ReP USP - Resultado da busca

Artigo de periodico
Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial (2024)
Rodes-Cabau, Josep; Ribeiro, Henrique Barbosa; Mohammadi, Siamak; Serra, Vicenc; Al-atassi, Talal; Iniguez, Andres; Vilalta, Victoria; Nombela-Franco, Luis; Sanchez, Jose Ignacio Saez de Ibarra; Pomerantzeff, Pablo Maria Alberto
Fonte: Circulation. Unidade: FM
Assuntos: PROCEDIMENTOS CIRÚRGICOS CARDIOVASCULARES, ESTENOSE DA VALVA AÓRTICA, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODES-CABAU, Josep et al. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial. Circulation, v. 149, n. 9, p. 644-655, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58829. Acesso em: 07 out. 2025.
APA
Rodes-Cabau, J., Ribeiro, H. B., Mohammadi, S., Serra, V., Al-atassi, T., Iniguez, A., et al. (2024). Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial. Circulation, 149( 9), 644-655. doi:10.1161/CIRCULATIONAHA.123.067326
NLM
Rodes-Cabau J, Ribeiro HB, Mohammadi S, Serra V, Al-atassi T, Iniguez A, Vilalta V, Nombela-Franco L, Sanchez JIS de I, Pomerantzeff PMA. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial [Internet]. Circulation. 2024 ; 149( 9): 644-655.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58829
Vancouver
Rodes-Cabau J, Ribeiro HB, Mohammadi S, Serra V, Al-atassi T, Iniguez A, Vilalta V, Nombela-Franco L, Sanchez JIS de I, Pomerantzeff PMA. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial [Internet]. Circulation. 2024 ; 149( 9): 644-655.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58829
Artigo de periodico
Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries (2023)
Alahmad, Barrak; Khraishah, Haitham; Roye, Dominic; Vicedo-Cabrera, Ana Maria; Guo, Yuming; Papatheodorou, Stefania I.; Achilleos, Souzana; Acquaotta, Fiorella; Armstrong, Ben; Saldiva, Paulo Hilário Nascimento
Fonte: Circulation.
Assuntos: DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, TEMPERATURAS EXTREMAS, MORTALIDADE, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALAHMAD, Barrak et al. Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries. Circulation, v. 147, n. 1, p. 35-46, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/51605. Acesso em: 07 out. 2025.
APA
Alahmad, B., Khraishah, H., Roye, D., Vicedo-Cabrera, A. M., Guo, Y., Papatheodorou, S. I., et al. (2023). Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries. Circulation, 147( 1), 35-46. doi:10.1161/CIRCULATIONAHA.122.061832
NLM
Alahmad B, Khraishah H, Roye D, Vicedo-Cabrera AM, Guo Y, Papatheodorou SI, Achilleos S, Acquaotta F, Armstrong B, Saldiva PHN. Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries [Internet]. Circulation. 2023 ; 147( 1): 35-46.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/51605
Vancouver
Alahmad B, Khraishah H, Roye D, Vicedo-Cabrera AM, Guo Y, Papatheodorou SI, Achilleos S, Acquaotta F, Armstrong B, Saldiva PHN. Associations between extreme temperatures and cardiovascular cause-specific mortality: results from 27 countries [Internet]. Circulation. 2023 ; 147( 1): 35-46.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/51605
Artigo de periodico
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial (2022)
Berg, David D.; Docherty, Kieran F.; Sattar, Naveed; Jarolim, Petr; Welsh, Paul; Jhund, Pardeep S.; Anand, Inder S.; Chopra, Vijay; Boer, Rudolf A. de; Kosiborod, Mikhail N.; Nicolau, Jose Carlos
Fonte: Circulation. Nome do evento: Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, VENTRÍCULO CARDÍACO, MODELOS DE RISCOS PROPORCIONAIS, IDOSOS, ENSAIO CLÍNICO, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERG, David D. et al. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, v. 145, n. 3, p. 158-169, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.057852. Acesso em: 07 out. 2025.
APA
Berg, D. D., Docherty, K. F., Sattar, N., Jarolim, P., Welsh, P., Jhund, P. S., et al. (2022). Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 145( 3), 158-169. doi:10.1161/CIRCULATIONAHA.121.057852
NLM
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Vancouver
Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, Boer RA de, Kosiborod MN, Nicolau JC. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial [Internet]. Circulation. 2022 ; 145( 3): 158-169.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.057852
Artigo de periodico
Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B (2022)
Bonaca, Marc P; Morrow, David A; Bergmark, Brian A; Berg, David D; Lima, Joao A. C; Hoffmann, Udo; Kato, Yoko; Lu, Michael T; Kuder, Julia; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: LIPOPROTEÍNAS, LIPOPROTEÍNAS HDL, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONACA, Marc P et al. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation, v. 146, n. 12, p. 907-916, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.122.059325. Acesso em: 07 out. 2025.
APA
Bonaca, M. P., Morrow, D. A., Bergmark, B. A., Berg, D. D., Lima, J. A. C., Hoffmann, U., et al. (2022). Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B. Circulation, 146( 12), 907-916. doi:10.1161/CIRCULATIONAHA.122.059325
NLM
Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Nicolau JC. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B [Internet]. Circulation. 2022 ; 146( 12): 907-916.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.122.059325
Vancouver
Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Nicolau JC. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B [Internet]. Circulation. 2022 ; 146( 12): 907-916.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.122.059325
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial (2022)
Furtado, Remo H. M.; Raz, Itamar; Goodrich, Erica L.; Murphy, Sabina A.; Bhatt, Deepak L.; Leiter, Lawrence A.; Mcguire, Darren K.; Wilding, John P. H.; Aylward, Philip; Dalby, Anthony J.; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: HIPERTENSÃO, INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS, RESULTADO DE TRATAMENTO, FÁRMACOS (SISTEMA CARDIOVASCULAR)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 07 out. 2025.
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Artigo de periodico
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy (2022)
Shah, Amil. M. M. ; Claggett, Brian ; Prasad, Narayana ; Li, Guichu ; Volquez, Mayra; Jering, Karola ; Cikes, Maja ; Kovacs, Attila ; Mullens, Wilfried; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: ECOCARDIOGRAFIA, INFARTO DO MIOCÁRDIO, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHAH, Amil. M. M. et al. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation, v. 146, n. 14, p. 1067-1081, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50457. Acesso em: 07 out. 2025.
APA
Shah, A. M. M., Claggett, B., Prasad, N., Li, G., Volquez, M., Jering, K., et al. (2022). Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation, 146( 14), 1067-1081. doi:10.1161/CIRCULATIONAHA.122.059210
NLM
Shah AMM, Claggett B, Prasad N, Li G, Volquez M, Jering K, Cikes M, Kovacs A, Mullens W, Nicolau JC. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy [Internet]. Circulation. 2022 ; 146( 14): 1067-1081.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50457
Vancouver
Shah AMM, Claggett B, Prasad N, Li G, Volquez M, Jering K, Cikes M, Kovacs A, Mullens W, Nicolau JC. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy [Internet]. Circulation. 2022 ; 146( 14): 1067-1081.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50457
Artigo de periodico
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction (2022)
Butler, Javed ; Filippatos, Gerasimos ; Siddiqi, Tariq Jamal; Ferreira, Joao Pedro ; Brueckmann, Martina ; Bocchi, Edimar Alcides ; Bohm, Michael ; Chopra, Vijay K. ; Giannetti, Nadia ; Iwata, Tomoko
Fonte: Circulation. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, HOMENS, MULHERES, PACIENTES INTERNADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTLER, Javed et al. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation, v. 146, n. 14, p. 1046-1055, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50467. Acesso em: 07 out. 2025.
APA
Butler, J., Filippatos, G., Siddiqi, T. J., Ferreira, J. P., Brueckmann, M., Bocchi, E. A., et al. (2022). Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation, 146( 14), 1046-1055. doi:10.1161/CIRCULATIONAHA.122.059755
NLM
Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi EA, Bohm M, Chopra VK, Giannetti N, Iwata T. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction [Internet]. Circulation. 2022 ; 146( 14): 1046-1055.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50467
Vancouver
Butler J, Filippatos G, Siddiqi TJ, Ferreira JP, Brueckmann M, Bocchi EA, Bohm M, Chopra VK, Giannetti N, Iwata T. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction [Internet]. Circulation. 2022 ; 146( 14): 1046-1055.[citado 2025 out. 07 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50467
Artigo de periodico-carta/editorial
Letter by Quintao and Cazita Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis".[Carta] (2021)
Quintão, Eder Carlos Rocha ; Cazita, Patricia M
Fonte: Circulation. Unidade: FM
Assuntos: LIPOPROTEÍNAS, PROTEÍNAS DE TRANSPORTE, SEPSES, CAMUNDONGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
QUINTÃO, Eder Carlos Rocha e CAZITA, Patricia M. Letter by Quintao and Cazita Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis".[Carta]. Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.053079. Acesso em: 07 out. 2025. , 2021
APA
Quintão, E. C. R., & Cazita, P. M. (2021). Letter by Quintao and Cazita Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis".[Carta]. Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1161/CIRCULATIONAHA.120.053079
NLM
Quintão ECR, Cazita PM. Letter by Quintao and Cazita Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis".[Carta] [Internet]. Circulation. 2021 ; 144( 6): E120-E121.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.053079
Vancouver
Quintão ECR, Cazita PM. Letter by Quintao and Cazita Regarding Article, "Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis".[Carta] [Internet]. Circulation. 2021 ; 144( 6): E120-E121.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.053079
Trabalho de evento-resumo periodico
The relationship between heart rate variability and common carotid artery intima-media thickness: the ELSA-Brasil (2020)
Hoshi, Rosangela; Lotufo, Paulo Andrade ; Santos, Itamar de Souza ; Goulart, Alessandra Carvalho ; Mill, José Geraldo; Dantas, Eduardo; Andreao, Rodrigo; Benseñor, Isabela Judith Martins
Fonte: Circulation. Nome do evento: EPI Lifestyle 2020 Scientific Sessions. Unidades: HU, FM
Assuntos: FREQUÊNCIA CARDÍACA, ARTÉRIAS CARÓTIDAS, ESTUDOS LONGITUDINAIS, SAÚDE DO ADULTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOSHI, Rosangela et al. The relationship between heart rate variability and common carotid artery intima-media thickness: the ELSA-Brasil. Circulation. Dallas: American Health Association. Disponível em: https://doi.org/10.1161/circ.141.suppl_1.P399. Acesso em: 07 out. 2025. , 2020
APA
Hoshi, R., Lotufo, P. A., Santos, I. de S., Goulart, A. C., Mill, J. G., Dantas, E., et al. (2020). The relationship between heart rate variability and common carotid artery intima-media thickness: the ELSA-Brasil. Circulation. Dallas: American Health Association. doi:10.1161/circ.141.suppl_1.P399
NLM
Hoshi R, Lotufo PA, Santos I de S, Goulart AC, Mill JG, Dantas E, Andreao R, Benseñor IJM. The relationship between heart rate variability and common carotid artery intima-media thickness: the ELSA-Brasil [Internet]. Circulation. 2020 ; 141[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.141.suppl_1.P399
Vancouver
Hoshi R, Lotufo PA, Santos I de S, Goulart AC, Mill JG, Dantas E, Andreao R, Benseñor IJM. The relationship between heart rate variability and common carotid artery intima-media thickness: the ELSA-Brasil [Internet]. Circulation. 2020 ; 141[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.141.suppl_1.P399
Trabalho de evento-resumo periodico
Interaction effects of diabetes and subclinical hypothyroidism on heart rate variability: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) (2020)
Hoshi, Rosangela; Santos, Itamar de Souza ; Dantas, Eduardo; Andreao, Rodrigo; Duncan, Bruce; Schmidt, Maria; Mill, José Geraldo; Lotufo, Paulo Andrade ; Benseñor, Isabela Judith Martins
Fonte: Circulation. Nome do evento: EPI Lifestyle 2020 Scientific Sessions. Unidades: HU, FM
Assuntos: FREQUÊNCIA CARDÍACA, DIABETES MELLITUS, HIPOTIREOIDISMO, ESTUDOS LONGITUDINAIS, SAÚDE DO ADULTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOSHI, Rosangela et al. Interaction effects of diabetes and subclinical hypothyroidism on heart rate variability: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Circulation. Dallas: American Health Association. Disponível em: https://doi.org/10.1161/circ.141.suppl_1.P125. Acesso em: 07 out. 2025. , 2020
APA
Hoshi, R., Santos, I. de S., Dantas, E., Andreao, R., Duncan, B., Schmidt, M., et al. (2020). Interaction effects of diabetes and subclinical hypothyroidism on heart rate variability: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Circulation. Dallas: American Health Association. doi:10.1161/circ.141.suppl_1.P125
NLM
Hoshi R, Santos I de S, Dantas E, Andreao R, Duncan B, Schmidt M, Mill JG, Lotufo PA, Benseñor IJM. Interaction effects of diabetes and subclinical hypothyroidism on heart rate variability: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) [Internet]. Circulation. 2020 ; 141[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.141.suppl_1.P125
Vancouver
Hoshi R, Santos I de S, Dantas E, Andreao R, Duncan B, Schmidt M, Mill JG, Lotufo PA, Benseñor IJM. Interaction effects of diabetes and subclinical hypothyroidism on heart rate variability: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) [Internet]. Circulation. 2020 ; 141[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.141.suppl_1.P125
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Fonte: Circulation. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 07 out. 2025.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
Martinez, Felipe A; Serenelli, Matteo; Nicolau, Jose Carlos ; Petrie, Mark C; Chiang, Chern-En; Tereshchenko, Sergey; Solomon, Scott D; Inzucchi, Silvio E; Kober, Lars; Kosiborod, Mikhail N
Fonte: Circulation. Unidade: FM
Assuntos: INSUFICIÊNCIA CARDÍACA, HIDROCARBONOS AROMÁTICOS, FATORES ETÁRIOS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 07 out. 2025.
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Artigo de periodico
Heart disease and stroke statistics - 2020 update: a report from the American Heart Association (2020)
Virani, Salim S; Bittencourt, Márcio Sommer
Fonte: Circulation. Unidade: HU
Assuntos: DOENÇAS CARDIOVASCULARES, EPIDEMIOLOGIA, FATORES DE RISCO, ESTATÍSTICA, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIRANI, Salim S e BITTENCOURT, Márcio Sommer. Heart disease and stroke statistics - 2020 update: a report from the American Heart Association. Circulation, v. 141, n. 9, p. e139-e596, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIR.0000000000000757. Acesso em: 07 out. 2025.
APA
Virani, S. S., & Bittencourt, M. S. (2020). Heart disease and stroke statistics - 2020 update: a report from the American Heart Association. Circulation, 141( 9), e139-e596. doi:10.1161/CIR.0000000000000757
NLM
Virani SS, Bittencourt MS. Heart disease and stroke statistics - 2020 update: a report from the American Heart Association [Internet]. Circulation. 2020 ; 141( 9): e139-e596.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIR.0000000000000757
Vancouver
Virani SS, Bittencourt MS. Heart disease and stroke statistics - 2020 update: a report from the American Heart Association [Internet]. Circulation. 2020 ; 141( 9): e139-e596.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIR.0000000000000757
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Fonte: Circulation. Unidade: FM
Assuntos: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 07 out. 2025.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Artigo de periodico
Heart disease and stroke statistics-2019 update: a report From the American Heart Association (2019)
Benjamin, Emelia J; Muntner, Paul; Bittencourt, Márcio Sommer
Fonte: Circulation. Unidade: HU
Assuntos: DOENÇAS CARDIOVASCULARES, EPIDEMIOLOGIA, FATORES DE RISCO, ESTATÍSTICA, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENJAMIN, Emelia J e MUNTNER, Paul e BITTENCOURT, Márcio Sommer. Heart disease and stroke statistics-2019 update: a report From the American Heart Association. Circulation, v. 139, n. 10, p. e56-e528, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIR.0000000000000659. Acesso em: 07 out. 2025.
APA
Benjamin, E. J., Muntner, P., & Bittencourt, M. S. (2019). Heart disease and stroke statistics-2019 update: a report From the American Heart Association. Circulation, 139( 10), e56-e528. doi:10.1161/CIR.0000000000000659
NLM
Benjamin EJ, Muntner P, Bittencourt MS. Heart disease and stroke statistics-2019 update: a report From the American Heart Association [Internet]. Circulation. 2019 ; 139( 10): e56-e528.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIR.0000000000000659
Vancouver
Benjamin EJ, Muntner P, Bittencourt MS. Heart disease and stroke statistics-2019 update: a report From the American Heart Association [Internet]. Circulation. 2019 ; 139( 10): e56-e528.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIR.0000000000000659
Artigo de periodico
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes (2019)
Roe, Matthew T; Li, Qian H; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Goodman, Shaun G; Harrington, Robert A; Jukema, J. Wouter; Lopez-jaramillo, Patricio; Nicolau, José Carlos
Fonte: Circulation. Unidade: FM
Assuntos: DIRETRIZES PARA A PRÁTICA CLÍNICA, ISQUEMIA MIOCÁRDICA, DISLIPIDEMIAS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROE, Matthew T et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, v. 140, n. 19, p. 1578-1589, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.042551. Acesso em: 07 out. 2025.
APA
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., et al. (2019). Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 140( 19), 1578-1589. doi:10.1161/CIRCULATIONAHA.119.042551
NLM
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Vancouver
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Artigo de periodico-carta/editorial
Letter by Vieira and Bocchi Regarding Article, ""Association Between Ambient Air Pollution and Cardiac Morpho-Functional Phenotypes [Carta]: Insights From the UK Biobank Population Imaging Study"" (2019)
Vieira, Jefferson Luis; Bocchi, Edimar Alcides
Fonte: Circulation. Unidade: FM
Assuntos: POLUIÇÃO AMBIENTAL, FENÓTIPOS, INSUFICIÊNCIA CARDÍACA, GRÃ-BRETANHA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VIEIRA, Jefferson Luis e BOCCHI, Edimar Alcides. Letter by Vieira and Bocchi Regarding Article, ""Association Between Ambient Air Pollution and Cardiac Morpho-Functional Phenotypes [Carta]: Insights From the UK Biobank Population Imaging Study"". Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038033. Acesso em: 07 out. 2025. , 2019
APA
Vieira, J. L., & Bocchi, E. A. (2019). Letter by Vieira and Bocchi Regarding Article, ""Association Between Ambient Air Pollution and Cardiac Morpho-Functional Phenotypes [Carta]: Insights From the UK Biobank Population Imaging Study"". Circulation. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1161/CIRCULATIONAHA.118.038033
NLM
Vieira JL, Bocchi EA. Letter by Vieira and Bocchi Regarding Article, ""Association Between Ambient Air Pollution and Cardiac Morpho-Functional Phenotypes [Carta]: Insights From the UK Biobank Population Imaging Study"" [Internet]. Circulation. 2019 ; 139( 15): 1857-1858.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038033
Vancouver
Vieira JL, Bocchi EA. Letter by Vieira and Bocchi Regarding Article, ""Association Between Ambient Air Pollution and Cardiac Morpho-Functional Phenotypes [Carta]: Insights From the UK Biobank Population Imaging Study"" [Internet]. Circulation. 2019 ; 139( 15): 1857-1858.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038033
Artigo de periodico
Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial (2019)
Steg, Philippe Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Bregeault, Marie-France; Dalby, Anthony J; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Fonte: Circulation. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 07 out. 2025.
APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840
NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Artigo de periodico
Work-family conflict and ideal cardiovascular health score in ELSA-Brasil baseline assessment (2019)
Rocco, Priscila T; Benseñor, Isabela M; Griep, Rosane Harter; Barreto, Sandhi Maria; Moreno, Arlinda B; Alencar, Airlane Pereira ; Lotufo, Paulo Andrade; Santos, Itamar S
Fonte: Circulation. Unidades: FM, IME, HU
Assuntos: ANÁLISE DE REGRESSÃO E DE CORRELAÇÃO, DOENÇAS CARDIOVASCULARES, ESTUDOS LONGITUDINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROCCO, Priscila T et al. Work-family conflict and ideal cardiovascular health score in ELSA-Brasil baseline assessment. Circulation, v. 139, 2019Tradução . . Disponível em: https://doi.org/10.1161/circ.139.suppl_1.P354. Acesso em: 07 out. 2025.
APA
Rocco, P. T., Benseñor, I. M., Griep, R. H., Barreto, S. M., Moreno, A. B., Alencar, A. P., et al. (2019). Work-family conflict and ideal cardiovascular health score in ELSA-Brasil baseline assessment. Circulation, 139. doi:10.1161/circ.139.suppl_1.P354
NLM
Rocco PT, Benseñor IM, Griep RH, Barreto SM, Moreno AB, Alencar AP, Lotufo PA, Santos IS. Work-family conflict and ideal cardiovascular health score in ELSA-Brasil baseline assessment [Internet]. Circulation. 2019 ; 139[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.139.suppl_1.P354
Vancouver
Rocco PT, Benseñor IM, Griep RH, Barreto SM, Moreno AB, Alencar AP, Lotufo PA, Santos IS. Work-family conflict and ideal cardiovascular health score in ELSA-Brasil baseline assessment [Internet]. Circulation. 2019 ; 139[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/circ.139.suppl_1.P354
Artigo de periodico
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial (2019)
Furtado, Remo H. M; Bonaca, Marc P; Raz, Itamar; Zelniker, Thomas A; Mosenzon, Ofri; Cahn, Avivit; Kuder, Julia; Murphy, Sabina A; Bhatt, Deepak L; Nicolau, José Carlos
Fonte: Circulation. Unidade: FM
Assuntos: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, INFARTO DO MIOCÁRDIO, ANTIDIABÉTICOS (HIPOGLICEMIANTES), RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, v. 139, n. 22, p. 2516-2527, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.039996. Acesso em: 07 out. 2025.
APA
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, 139( 22), 2516-2527. doi:10.1161/CIRCULATIONAHA.119.039996
NLM
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996
Vancouver
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2025 out. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Nome do evento

Agência de fomento

Indexado em

Afiliação dos autores externos normalizada

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos